Chembio Diagnostics (CEMI +0.2%) bucks a weak tape after saying it won a $750K cooperative research agreement with a US government agency to develop rapid point-of-carediagnostic tests for five infectious diseases associated with febrile illness and to multiplex them into one assay. The eight-month project also hopes to optimize the test for use with a mobile reader that incorporates cell phone technology to enable the results to be recorded, transmitted and monitored remotely via a cloud system, in real-time.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs